TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04364269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive hard capsules of Placebo, twice a day.
Study: NCT03743246
Drug: JCAR017
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCAR017
Study: NCT03743246
Drug: Lymphodepleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting
Study: NCT03743246
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT00979056
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablet, Oral Use
Study: NCT01490580
Drug: atropine + atracurium + sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
Study: NCT00056979
Drug: CAMPATH-1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00972504
Drug: GSK835726 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK835726 10mg tablet
Study: NCT00972504
Drug: GSK1004723 1000mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1004723 1000mcg nasal spray solution
Study: NCT00972504
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match actives
Study: NCT01300312
Drug: Eperisone hydrochloride and Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
Study: NCT03259087
Drug: MK-3866
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
Study: NCT01849562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01782885
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
Study: NCT02028533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02304523
Drug: CDFR0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study: NCT02304523
Drug: CDFR0613
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study: NCT02304523
Drug: Coolprep Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study: NCT03498170
Drug: BCT197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of BCT197
Study: NCT02114463
Drug: flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Study: NCT00269880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
Study: NCT00269880
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
Study: NCT00861458
Drug: Pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 750 mg PF-00868554 as a solution and tablets.
Study: NCT01802632
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
Study: NCT01983306
Drug: SP-333 1 mg
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01983306
Drug: SP-333 3 mg
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01983306
Drug: SP-333 6 mg
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01983306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04209049
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Study: NCT00637234
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
Study: NCT00637234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 300 mg tablets, up to 600 mg three times daily
Study: NCT05561036
Drug: Liposome doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
Study: NCT02416739
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
Study: NCT00279916
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily.
Study: NCT01141322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
Study: NCT01444235
Drug: Custodiol-N
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
Study: NCT01444235
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
Study: NCT00633360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily by mouth
Study: NCT01964287
Drug: GEMBRAX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01964287
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02517307
Drug: Intralipid/Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
Study: NCT02517307
Drug: Glycerol/Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
Study: NCT00650767
Drug: ARRY-438162, MEK inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT00650767
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04346004
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery.
Study: NCT01235507
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: stable dose as prescribed
Study: NCT01681290
Drug: CBX129801
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03451435
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
Study: NCT00432185
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% PEP005 Gel
Study: NCT00926185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT02770248
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT03893032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral-administration placebo tablet
Study: NCT03384940
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
Study: NCT01668849
Drug: Lortab, Fentanyl patch, mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
Study: NCT00002675
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00704366
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, tablet, once daily, dose will be variable
Study: NCT00638690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets once daily until disease progression
Study: NCT00043082
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous q 4 weeks
Study: NCT02207075
Drug: [C11]PK-1195 PET scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan with tracer \[C11\]PK-1195
Study: NCT03778580
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03659201
Drug: Neosil complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, during 24 weeks.
Study: NCT03659201
Drug: Pantogar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, placebo for 12 weeks and pantogar for 12 weeks.
Study: NCT00961636
Drug: Placebo to ERN/LRPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
Study: NCT01979913
Drug: Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02160106
Drug: TEW-7197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Study: NCT01768676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03958513
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
Study: NCT02283840
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00643968
Drug: EFV+TDF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00643968
Drug: EFV+3TC+TDF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04567667
Drug: Kinevac®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03812783
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT03812783
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
Study: NCT04327791
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered PO once
Study: NCT03072264
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
Study: NCT02722200
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
Study: NCT00555880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00799266
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT00799266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00154440
Drug: proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00154440
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02830152
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
Study: NCT04178109
Drug: Dexketoprofen/tramadol (27mg/75mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
Study: NCT00031473
Drug: Virazole (Ribavirin) Inhalation Solution
Normalized name: Virazole Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05089643
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
Study: NCT01276639
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral BID, Continuous treatment for 52 Weeks
Study: NCT01276639
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral BID, Continuous treatment for 52 Weeks
Study: NCT01276639
Drug: Placebo/CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study: NCT01276639
Drug: Placebo/CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study: NCT01025843
Drug: MK-5478
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
Study: NCT01025843
Drug: Comparator: Pbo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03967886
Drug: YYD601 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take drugs an hour before breakfast.
Study: NCT00174317
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02297386
Drug: [18F] DIHYDRO-TESTOSTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03639324
Drug: Dose combination 1-3
Normalized name: Habitrol Combination Kit Steps 1-3 Transdermal System (56)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID of idelalisib + 200 mg QD of venetoclax
Study: NCT03639324
Drug: Sub-Trial: Dose combination 2-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID of idelalisib + 100 mg QD of venetoclax
Study: NCT03639324
Drug: Sub-Trial: Dose combination 2-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg BID of idelalisib + 100 mg QD of venetoclax
Study: NCT02987465
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
Study: NCT02577523
Drug: ND0612 (Levodopa/Carbidopa solution)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
Study: NCT02577523
Drug: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
Study: NCT02987465
Drug: BQ 123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
Study: NCT02722668
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1: 50 mg/kg IV over 2 hours Day -6
Study: NCT03138421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00911066
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
Study: NCT01380769
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRLX101 is administered at 15mg/m2 IV every other week
Study: NCT02757144
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 tablets
Study: NCT02757144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study: NCT04039958
Drug: Soviredia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study: NCT04095182
Drug: Placebo for Zebinix 400mg
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study: NCT04095182
Drug: Placebo for Zebinix 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study: NCT04095182
Drug: Placebo for Zebinix 1600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study: NCT01391624
Drug: Paraffin + # 2 dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules of mineral oil (ineffective) for 8 weeks.
Study: NCT03499184
Drug: Amoxil 500 mg Oral Capsule
Normalized name: Amoxil 500 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically administered Amoxil 500 mg thrice daily
Study: NCT00644150
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
Study: NCT02384928
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
Study: NCT03400852
Drug: MNK-1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNK-1411 (1 mg/mL suspension) for subcutaneous injection
Study: NCT02241668
Drug: 3'-Deoxy-3'-18f-Fluorothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
Study: NCT00950404
Drug: Formulation B ODT tablet 50 mg
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
Study: NCT00950404
Drug: Formulation C ODT tablet 50 mg
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ODT, 50 mg, single dose administered without water
Study: NCT00950404
Drug: Formulation D ODT tablet 50 mg
Normalized name: Rho(D) Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODT, 50 mg, single dose, administered without water
Study: NCT00531518
Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, daily, generally at lower than manufacturer's recommendations
Study: NCT03921450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz stimulation with the placebo TMS coil without any magnetic emission
Study: NCT00545090
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 6 months
Study: NCT00721448
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9